Lenvatinib and pembrolizumab plus FOLFOX-hepatic arterial infusion chemotherapy in locally advanced, potentially resectable hepatocellular carcinoma

doi:10.4251/wjgo.v18.i7.118522

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 7

This Article

(20)

(17)

(0)

(290)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Jul 15, 2026; 18(7): 118522
Published online Jul 15, 2026. doi: 10.4251/wjgo.v18.i7.118522

Table 5 Multivariate analysis of survival factors in 38 patients with initially unresectable hepatocellular carcinoma

Factors	β	Wald	Hazard ratio	P value	95%CI
Gender				0.060	0.937-24.376
Male	-	-	Reference
Female	1.564	3.541	4.780
Hepatitis				0.107	0.691-44.754
Negative	-	-	Reference
Positive	1.715	2.599	5.559
Antiviral therapy				0.691	0.448-3.359
Negative	-	-	Reference
Positive	0.205	0.159	1.227
Lesion numbers				0.461	0.518-4.275
1	-	-	Reference
≥ 2	0.397	0.544	1.488
Conversion rate
Fail	-	-	Reference
Success	-1.609	8.263	0.200	0.004	0.067-0.599

Full Size Table

Citation: Chen X, Liao H, Chen J, Peng LH, Zhang JH, Xuyun XX, Chen YJ, Chen T. Lenvatinib and pembrolizumab plus FOLFOX-hepatic arterial infusion chemotherapy in locally advanced, potentially resectable hepatocellular carcinoma. World J Gastrointest Oncol 2026; 18(7): 118522
URL: https://www.wjgnet.com/1948-5204/full/v18/i7/118522.htm
DOI: https://dx.doi.org/10.4251/wjgo.v18.i7.118522

Chen X, Liao H, Chen J, Peng LH, Zhang JH, Xuyun XX, Chen YJ, Chen T. Lenvatinib and pembrolizumab plus FOLFOX-hepatic arterial infusion chemotherapy in locally advanced, potentially resectable hepatocellular carcinoma. World J Gastrointest Oncol 2026; 18(7): 118522 [DOI: 10.4251/wjgo.v18.i7.118522]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.